Impact of zolmitriptan on migraineur lifestyle - An observational study

Journal of Outcomes Research

Volumn 3, Issue 1-10, 1999, Pages 1-9

  Baker, A ^a   Sawyer, James ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Health economic; Migraine; Observational study; Zolmitriptan

Indexed keywords

ZOLMITRIPTAN;

ABSENTEEISM; ADULT; ARTICLE; CLINICAL ARTICLE; CONSULTATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; DRUG UTILIZATION; FEMALE; HUMAN; LIFESTYLE; MALE; MIGRAINE; OUTCOMES RESEARCH; QUESTIONNAIRE; UNITED KINGDOM;

EID: 0033303264     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors
2. Migraine prevalence. A review of population-based studies
3. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain
4. Quality of life and well-being of headache patients: Measurement by the Medical Outcomes Study instrument
5. The quality of life of migraineurs: A cross-sectional profile
6. Measuring the functional status of patients with headache
7. Loss of productivity and quality of life in migraine sufferers among French workers: Results from the DAZEL cohort
8. Migraine patients experience poorer subjective well-being/quality of life even between attacks
9. Functional status and well being of patients with chronic conditions. Results from the medical outcomes study
10. Functional status and well being of depressed patients. Results from the medical outcomes study
11. Does quality of life differ among headache diagnoses. Analysis using the medical outcomes study instrument
12. The economic burden of migraine to society
13. Economic and social impact of migraine
14. Burden of Migraine: A review of its socioeconomic impact
15. IB/D agonist zolmitriptan (311C90): Are brain stem sites therapeutic targets in migraine?
16. IB/ID agonist for migraine
17. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
18. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study
19. IB/ID receptor agonist for the acute oral treatment of migraine: A multicenter, dose-range finding study
20. The long-term tolerability and efficacy of oral zolmitriptan ('Zomig', 311C90) in the acute treatment of migraine
21. 'Zomig' is consistently effective in the acute treatment of migraine
22. Instrument development: Migraine-specific quality of life measure (MSQOL)
23. Consistency of meaningful migraine relief and quality of life in patients treated with Zomig™
24. A nationwide survey of migraine in France: Prevalence and clinical features in adults
25. A Canadian population survey on the clinical, epidemiological and societal impact of migraine and tension-type headache, Part II
26. Epidemiology of headache in a general population - A prevalence study
27. Suffering in silence
28. Prevalence of migraine headache in Canada: A population-based survey
29. Prevalence of adult migraine in general practice
30. Maximising migraine relief with zolmitriptan: Preliminary data from an open study with >25000 treated attacks